Background {#section1-1179547620906863}
==========

Angiomyolipomas are relatively rare benign tumors of the kidneys, with a risk of spontaneous hemorrhage that may lead to severe retroperitoneal bleedings. In serial ultrasound screenings, angiomyolipomas could be found in 0.1% of the male and in 0.22% of the female population, respectively.^[@bibr1-1179547620906863],[@bibr2-1179547620906863]^ Angiomyolipomas consist of abnormal blood vessels, smooth muscle cells, and fat cells in varying amounts. The structurally altered blood vessels are prone to the formation of aneurysms and to ruptures, as they bear no internal elastic lamina and their smooth muscle is replaced by fibrous tissue, which makes the vessels more rigid and tortuous.^[@bibr3-1179547620906863][@bibr4-1179547620906863]-[@bibr5-1179547620906863]^

A review of the literature showed that almost 60% of patients present with clinical symptoms,^[@bibr2-1179547620906863]^ most typically with flank pain, a palpable tender mass, and macroscopic or microscopic hematuria. Of importance is the possible complication of a potentially life-threatening hemorrhage. Nevertheless, a significant number of angiomyolipomas are detected incidentally on radiographic findings, where the presence of fatty tissue in the renal tumor is essential to diagnose an angiomyolipoma using magnetic resonance imaging (MRI) or computed tomography (CT) studies.^[@bibr2-1179547620906863]^

In 80% of the patients, angiomyolipomas occur sporadically, whereas 20% are associated with tuberous sclerosis complex (TSC), an autosomal dominant systemic disorder predisposing to benign tumor formation in multiple organs. Both sporadic and in TSC-associated angiomyolipomas affect women in almost 90% of cases.^[@bibr2-1179547620906863],[@bibr6-1179547620906863]^

Established indications for therapy are clinically symptomatic lesions of any size or a tumor size exceeding 4 cm of diameter. Treatment options include nephrectomy, partial nephrectomy, and selective arterial embolization. Recent therapy strategies are focusing on the nephron-sparing procedure of embolization. Embolization therapy of angiomyolipomas has been performed with variety of agents used for embolization, such as gelatin, polyvinyl alcohol, coils, foam, ethanol, and combinations of these agents.^[@bibr6-1179547620906863][@bibr7-1179547620906863][@bibr8-1179547620906863]-[@bibr9-1179547620906863]^ Ethanol is used alone or in combination with other agents such as oil or microparticles.^[@bibr10-1179547620906863][@bibr11-1179547620906863]-[@bibr12-1179547620906863]^ Pure ethanol is a widely used embolization agent, but there is only scarce data using it for this indication.^[@bibr13-1179547620906863]^ In the literature, predominately oil or microparticles are added to ethanol when treating angiomyolipomas.^[@bibr10-1179547620906863][@bibr11-1179547620906863]-[@bibr12-1179547620906863]^ In this study, we want to report on the findings of using pure 96% ethanol.

Patients and Methods {#section2-1179547620906863}
====================

We analyzed all patients who underwent selective arterial embolization of renal angiomyolipomas at our institution between March 2015 and May 2017. In this period, no patients referred to our institution were excluded from this treatment option. Data on differently treated patients by other medical specialties were not available. In total, 5 patients were treated in 8 embolization sessions. In all of them, 96% ethanol was used. Written informed consent was obtained from all patients.

Treatment {#section3-1179547620906863}
---------

The embolization procedures were planned electively in general anesthesia for precise cardiopulmonary monitoring and because of the painful nature of this procedure when performed without general anesthesia. To modulate the inflammatory reaction,^[@bibr14-1179547620906863]^ a single dose of prednisone 125 mg was administered intravenously before the procedure (Solu-Medrol; Pfizer PFE Switzerland, Zurich, Switzerland). After the intervention, oral dexamethasone (Dexamethason Galepharm, Zurich, Switzerland) was routinely prescribed for 4 or 7 days at an initial dose of 8 mg/d and was weaned off. For pain management, nonsteroidal anti-inflammatory drugs (NSAIDs) were prescribed.

Femoral arteries were accessed using a 5 F sheath (Radiofocus introducer II, Terumo, Tokyo, Japan). Subsequently, abdominal aortographies were performed followed by catheterization of the target renal arteries (C1; Cordis, Miami Lakes, FL, USA). Super-selective angiographies were performed to identify the supplying vessels of the angiomyolipomas. Then, embolizations were performed by slowly instilling ethanol under free flow conditions. Due to lack of visibility of ethanol under fluoroscopy, it was either mixed with contrast in a ratio 5:1 or it was applied in very small quantities followed by super-selective repeated angiograms. Injection was performed using 1 mL insulin syringes for better low flow control. Repeated injections were delayed by at least 1 to 2 minutes always followed by fluoroscopic contrast injection to estimate effect of ethanol embolization and to fill the microcatheter with contrast for better tracking the course of embolization.

Successful occlusions of the tumors supplying vessels were verified in a subsequent control angiography. The patients were discharged the next day. Routine postintervention ultrasound was performed either on the first day after the procedure or within 4 weeks. Postintervention cross-sectional imaging was performed with MRI or CT scans at the discretion of the referring specialists. Therapeutic success was defined as an eliminated arterial perfusion signal in duplex sonography and MRI or CT-scan.

Results {#section4-1179547620906863}
=======

Patients {#section5-1179547620906863}
--------

Five female patients aged 38 to 63 years (median age: 52.2 years) were treated in 8 elective embolization sessions. Details on these patients (labeled A through E) are summarized in [Table 1](#table1-1179547620906863){ref-type="table"}.

###### 

Results and patient characteristics (patients labeled A through E).

![](10.1177_1179547620906863-table1)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient                                                           A                                B                     C                                                        D                      E
  ----------------------------------------------------------------- -------------------------------- --------------------- -------------------------------------------------------- ---------------------- ---------------------------------------------------------------------------------
  Age, y                                                            58                               63                    42                                                       60                     38

  Sex                                                               Female                           Female                Female                                                   Female                 Female

  Type                                                              Sporadic                         Sporadic              Sporadic                                                 Sporadic               TSC

  Extent of AMLs                                                    Multiple, bilateral              2, unilateral         1                                                        2, unilateral          Multiple, bilateral

  Size of largest AML (cm)                                          5.8                              4.5                   5.6                                                      10.8                   6

  Initial diagnostic method                                         CT scan, ultrasound              CT scan               MRI                                                      CT scan                CT scan, MRI

  Prior surgical treatment of the AML                               Yes                              No                    No                                                       No                     Yes

  Initial symptoms                                                  Data not available               Side pain             Asymptomatic                                             Side pain, hematuria   Asymptomatic

  Indication for treatment                                          Size                             History of bleeding   Size                                                     Size                   Size

  No. of treatments; if 2, planned (p)/unplanned, u))               2; (p)                           1                     1                                                        2; (u)                 2; (p)

  Amount of alcohol used in each procedure (no. of procedure: mL)   1: 8.5\                          2.2                   10.3                                                     1: 13\                 1: 8\
                                                                    2: 5.5                                                                                                          2: 1                   2: 13.3

  Primary angiographic success                                      Yes                              Yes                   Yes                                                      Yes                    Yes, 1 AML not accessible

  Treatment success on postinterventional sonography                Yes                              Yes                   Yes                                                      Yes                    Unfavorable sonographic conditions

  Follow-up CT/MRI available                                        No                               No                    Yes                                                      Yes                    Yes

  Size of biggest AML at follow-up/size reduction (cm)                                                                     4.1/1.5                                                  8.8/2.0                3.4/2.6

  Complications                                                     Mild postembolization syndrome   None                  Mild postembolization syndrome, nontarget embolization   None                   Pseudoaneurysm, moderate postembolization syndrome, worsening of renal function
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AML, angiomyolipoma; CT, computed tomography; MRI, magnetic resonance imaging; TSC, tuberous sclerosis complex.

One patient (patient C) had a single angiomyolipoma, 2 patients (patients B and D) had 2 unilateral angiomyolipomas, and 2 other patients (patients A and E) had multiple bilateral angiomyolipomas, one of which was associated with TSC (patient E). Two patients (patients A and E) had a history of prior partial nephrectomy and in the same 2 patients, a planned second embolization was performed due to the multilobular tumor characteristics. In 1 patient (patient D), a reintervention was performed due to recurrent symptoms.

The treated angiomyolipomas had diameters ranging between 4.5 and 10.8 cm. Indications for the initial treatment were a large tumor size in 4 cases (patients A, C, D, E) and a history of bleeding in 1 case (patient B; [Figure 1](#fig1-1179547620906863){ref-type="fig"}), respectively. In the latter patient, an elective embolization was performed 6 months after a self-limiting retroperitoneal hemorrhage occurred. A median amount of 7.7 mL of alcohol was used per embolization session (range: 1.0-13.3 mL).

![CT scan (arterial phase) of a 63-year-old female patient (patient B) who presented with a history of flank pain for 5 days, showing an angiomyolipoma-associated retroperitoneal hematoma. No active bleeding was detected; an elective embolization procedure of the angiomyolipoma was scheduled. CT indicates computed tomography.](10.1177_1179547620906863-fig1){#fig1-1179547620906863}

Efficacy {#section6-1179547620906863}
--------

In all of our 5 patients, postinterventional control angiography showed complete angiographic elimination of the targeted angiomyolipoma, which was defined as treatment success. [Figure 2](#fig2-1179547620906863){ref-type="fig"} (patient A) and [Figure 3](#fig3-1179547620906863){ref-type="fig"} (patient D) show preembolization and postembolization angiograms. During follow-up examinations, therapeutic success could be confirmed in all cases using ultrasound, MRI, or CT scans. In 4 of the 5 patients (in patients A, B, C, D), no arterial perfusion was detectable in the postintervention ultrasound scan. In 1 patient (patient E), sonographic assessment was limited due to impaired ultrasound conditions. In 3 patients, follow-up cross-sectional imaging was initiated by the referring physicians 3 to 12 months after the intervention (patients C, D, and E). Complete target lesion elimination of the perfusion signal was confirmed in 1 patient (patient C), and a significant reduction of the target lesion perfusion was demonstrated in 2 patients (patients D and E). In all 3 patients, significant tumor size reductions were shown, ranging between 1.5 and 4.6 cm. Patient E had multiple angiomyolipoma s in both kidneys. Due to vasospasm, 1 of the 5 biggest lesions was not accessible during the initial procedure in this patient.

![Preembolization (A) and postembolization angiogram (B) of a large angiomyolipoma (maximum diameter 5.8 cm) of the right kidney in a 58-year-old female patient (patient A) with multiple bilateral angiomyolipomas.](10.1177_1179547620906863-fig2){#fig2-1179547620906863}

![Embolization of a large angiomyolipoma located in the right kidney of a 60-year-old female patient (patient D). Showing the (A) initial selective angiogram, (B) a super-selective angiogram, and (C) the final angiogram after the first super-selective arterial embolization.](10.1177_1179547620906863-fig3){#fig3-1179547620906863}

In 1 patient (patient D), an additional embolization had to be performed due to recurrent symptoms of abdominal pain and unexplained hematuria, although procedural success had been demonstrated in cross-sectional studies after the first embolization with an only weak residual arterial perfusion and a 20% size reduction in MRI. This was confirmed by re-angiography so that a small dose of 1 mL of 96% ethanol was applied ([Figure 4](#fig4-1179547620906863){ref-type="fig"}). The final CT scan demonstrated a size reduction from 108 to 59 mm after both procedures ([Figure 5](#fig5-1179547620906863){ref-type="fig"}).

![Patient D underwent an unplanned re-intervention due to recurrent symptoms. (A) Residual perfusion of the angiomyolipoma could be demonstrated and (B) the final angiogram shows an elimination of the perfusion signal after embolization with an overlaying signal from lumbar arteries.](10.1177_1179547620906863-fig4){#fig4-1179547620906863}

![(A) Preinterventional and (B) postinterventional CT scan (arterial phase) of the same patient (patient D). A size reduction of the angiomyolipoma from 108 to 59 mm could be demonstrated after 2 embolization sessions. CT indicates computed tomography.](10.1177_1179547620906863-fig5){#fig5-1179547620906863}

Safety {#section7-1179547620906863}
------

Mild and self-limiting postembolic flank pain occurred in 2 patients (patients A and C). In 1 patient (patient E), moderate to severe abdominal pain required rehospitalization for analgetic therapy. In the same patient, a femoral pseudoaneurysm was detected at the puncture site which was treated successfully by ultrasound-guided compression. In this patient, mildly increased creatinine (from 86 to 99 µmol/L) and new onset of arterial hypertension was detected after the intervention. This complex patient had a history of a prior partial nephrectomy, due to the vast extent of multiple bilateral angiomyolipomas associated with TSC. Two elective consecutive embolizations were performed in her targeting multiple tumors.

Discussion {#section8-1179547620906863}
==========

Angiomyolipomas are benign tumors of the kidney that require interdisciplinary management. Therapeutic options include partial or total nephrectomy.^[@bibr6-1179547620906863]^ However, nephron-sparing endovascular embolization has evolved as the standard therapy.

There is a variety of agents used for embolization.^[@bibr6-1179547620906863],[@bibr8-1179547620906863][@bibr9-1179547620906863][@bibr10-1179547620906863][@bibr11-1179547620906863][@bibr12-1179547620906863][@bibr13-1179547620906863]-[@bibr14-1179547620906863]^ In our practice, we preferably use pure 96% ethanol for tumor and vascular malformation embolizations.^[@bibr15-1179547620906863]^

Ethanol denaturates proteins resulting in intravascular thrombosis and subsequent tissue infarction and fibrotic and necrotic tissue remodeling.^[@bibr14-1179547620906863]^ Application techniques of undiluted 96% ethanol may vary. Besides directly injecting alcohol under free flow, different other application options are described in the literature. Some authors describe using flow control devices such as balloons to attenuate the arterial perfusion or the venous drainage of the tumor to enhance the denaturating effect of the alcohol on the endothelial cells by increasing the contact time. Authors also describe that the alcohol can be aspirated after being left in situ for a minute, when the perfusion has been blocked with an occlusion balloon.^[@bibr11-1179547620906863][@bibr12-1179547620906863]-[@bibr13-1179547620906863]^ In our series, we injected 96% ethanol under free flow conditions, in the absence of flow control devices to avoid locoregional toxic effects seen with prolonged exposure to undiluted ethanol.

Possible adverse events of alcohol embolization include cardiopulmonary complications, which may lead to acute pulmonary hypertension and acute right heart failure as a consequence of pulmonary artery spasms or extensive microthromboembolization. Therefore, the intervention should be performed under close cardiopulmonary monitoring. However, according to Shin et al,^[@bibr16-1179547620906863]^ the risk of cardiopulmonary complications is low when \<0.14 mL ethanol/kg body weight are applied every 10 minutes, with a maximum dose of \<1 mL/kg body weight per session.^[@bibr15-1179547620906863][@bibr16-1179547620906863][@bibr17-1179547620906863][@bibr18-1179547620906863]-[@bibr19-1179547620906863]^ After having used pure ethanol for many years for treating of vascular malformations at our institution, we prefer to perform these procedures in general anesthesia, due to the painful nature of alcohol embolization as well as for precise cardiopulmonary monitoring.

In our series of patients, we had a primary angiographic success rate of 100% of the treated tumors. Regarding adverse events, in 1 of our 5 patients, a mild worsening of an already preexisting reduced renal function (pre- and postprocedure chronic kidney disease \[CKD\] stage II) was noted after the intervention together with new arterial hypertension. As the final angiogram showed intact healthy renal parenchyma, a nephrotoxic effect of the contrast was suspected in this long and complex procedure targeting multiple bilateral angiomyolipomas in 1 session. An additional third planned treatment session, which was considered necessary because of arterial spasm in one of the supplying arteries of 1 remaining angiomyolipoma, has not been performed to date. The consensus with the referring specialist was to postpone the intervention to not jeopardize kidney function further in this polymorbid patient. Of note, follow-up MRI showed only a residual perfusion signal in the treated angiomyolipomas and a size regression in most of the treated lesions in this patient.

In another patient, a limited nontarget embolization could be demonstrated in the final angiogram, affecting 10% to 15% of the vital kidney tissue. However, this finding remained asymptomatic, with no effects on renal function. As pure ethanol is not visible under fluoroscopy, possible nontarget embolization due to backflow is a concern. To limit this risk, ethanol either was mixed with contrast or was applied undiluted in only very small quantities using a 1-mL insulin syringes followed by super-selective repeated angiograms.

Nontarget embolizations are possible adverse events of any embolization therapy; however, these are rare events. In a literature review by Murray et al^[@bibr6-1179547620906863]^ the total postinterventional morbidity in patients undergoing embolization procedures for the treatment of angiomyolipomas was described in 6.9% of patients, which included nontarget embolization in 2.3% of patients, respiratory complications in 2.0%, abscess formation in 1.6%, active retroperitoneal hemorrhage in 1.0%, allergic reactions in 0.6%, urinary retention in 0.6%, urinary tract infections in 0.3%, femoral artery damage requiring repair in 0.3%, and renal artery spasm in 0.3% of patients.

An additional embolization was performed in 1 patient due to recurrent symptoms and otherwise not explained hematuria, despite radiological success of the treatment. Murray et al^[@bibr6-1179547620906863]^ in their systemic review describe that re-embolizations or surgeries are required in 20.9% of angiomyolipomas treated with embolization (at a medium follow-up time of 39 months). The most common indications for re-embolization procedures are described as revascularization on follow-up imaging (30.0%), unchanged or increasing tumor size (22.6%), refractory or recurring symptoms (16.7%), and acute retroperitoneal hemorrhage in 14.3% of the cases. However, re-angiography in our patient demonstrated subtotal angiomyolipoma occlusion so that only 1 mL of alcohol was applied. Because symptoms persisted after successful reintervention, an alternative explanation for the symptoms seems likely.

An inherent limitation of a case series of patients undergoing embolization procedures is that the included subjects have been previously chosen for this treatment modality and not for another one. Our findings therefore are not necessarily applicable to all patients with angiomyolipomas.

In conclusion, our case report and literature review provides evidence that embolization using 96% ethanol is an option to treat renal angiomyolipomas. Please find teaching points and a quiz in the [appendix](#app1-1179547620906863){ref-type="app"}.
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Teaching points {#section9-1179547620906863}
===============

Established indications for embolization are clinically symptomatic angiomyolipomas (AMLs) of any size or a tumor size exceeding 4 cm of diameter. Pure, 96% ethanol is one of a variety of embolic agents currently being used.

Questions and answers {#section10-1179547620906863}
=====================

1.  1. Which systemic side effects are possible when using pure ethanol as embolic agent for AMLs? (multiple answers possible)Signs of alcohol intoxication after the procedure (applies)Cardiopulmonary complications such as acute pulmonary hypertension and acute right heart failure (applies)Elevated levels of blood alcohol during and after the procedure (applies)High risk of pulmonary artery spasm when \<0.14 mL ethanol/kg body weight are applied every 10 minutes, with a maximum dose of \<1 mL/kg body weight per sessionNone of the above

Explanation: Systemic effects of ethanol are well known^[@bibr16-1179547620906863]^, including serious cardiopulmonary complications, especially when exceeding a weight and time depending ethanol dosage.

1.  2. In which of the following cases an embolization therapy should be considered? (multiple answers possible)An incidental finding of an AML (diameter 3.2 cm) in a 45-year-old female patient during a routine check upA 35-year-old female patient with a completely asymptomatic AML in the right kidney (diameter 4.5 cm) (applies)A patient with a small AML who has a history of self-limiting bleeding and was diagnosed 2 weeks after the suspected bleeding episode (applies)A hemodynamically stable patient with an acute bleeding of an AML (diameter 5 cm) (applies)A 60-year-old female patient with a 3-cm AML of the right kidney and a history of so far unexplained flank pain on the right side (applies)

Explanation: Indication for therapy is symptomatic AMLs of any size (including flank pain and history of bleeding) as well as tumors exceeding 4 cm in diameter^[@bibr6-1179547620906863]^. An acutely bleeding AML in a stable patient is an established indication for embolization therapy.

1.  3. AMLs are associated with which of the following symptoms? (multiple answers possible)Flank pain and/or palpable tender tumor mass (applies)Microscopic or macroscopic hematuria (applies)Retroperitoneal bleeding (applies)Renal failure (applies)Family history of polycystic kidney disease

Explanation: AMLs when symptomatic present most typically with flank pain, a palpable tender mass, and macroscopic or microscopic hematuria^[@bibr2-1179547620906863]^. Other symptoms include nausea and vomiting, fever, hypertension, anemia, renal failure, as well as potentially life-threatening hemorrhage.

1.  4. AMLs occur sporadically or in association with tuberous sclerosis complex (TSC), an autosomal dominant systemic disorder predisposing to benign tumor formation in multiple organs. Which of the following statements is true? (multiple answers possible)Sporadic AMLs affect more female patients, TSC-associated AMLs affect more male patientsAbout 50% of patients with TSC develop AMLs (applies)TSC-associated AMLs tend to bleed more compared with sporadic AMLs (applies)TSC is an autosomal dominant disorder (applies)On average, AMLs are diagnosed at the age of 50 in both groups

Explanation: In 20% of patients, AMLs are associated with TSC, an autosomal dominant multiorgan disorder^[@bibr2-1179547620906863]^. About 50% of patients with TSC develop AMLs. TSC-associated AMLs occur at a younger age compared with sporadic AMLs, with a mean age at diagnosis of 30 versus 50 years, and they are associated with a greater tumor size, the presence of multiple renal AMLs, and a greater risk of hemorrhage. Both sporadic and TSC-associated AMLs affect women in almost 90% of cases.

1.  5. Which are among the 5 most common factors associated with postinterventional morbidity as described by Murray et al? (multiple answers possible)No-target embolization (applies)Abscess formation (applies)Active retroperitoneal bleeding (applies)Respiratory complications (applies)Femoral pseudoaneurysm requiring repair

Explanation: In Murray's review^[@bibr6-1179547620906863]^ on embolization of AMLs using different embolic agents, the total postinterventional morbidity was described in 6.9% of patients. The most common factors were nontarget embolization (2.3%), respiratory complications (2.0%), abscess formation (1.6%), active retroperitoneal hemorrhage (1.0%), and allergic reactions and urinary retention (both 0.6%).
